[CAS NO. 2869954-53-8]  Werner syndrome RecQ helicase-IN-4

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2869954-53-8]

Catalog
HY-148741
Brand
MCE
CAS
2869954-53-8

DESCRIPTION [2869954-53-8]

Overview

MDL-
Molecular Weight666.65
Molecular FormulaC32H33F3N8O5
SMILESO=C(N1CCN(CC1)C2=C(CC)N(CC(NC3=CC=C(C(F)(F)F)C=C3C)=O)C4=NC(C5=CCOCC5)=NN4C2=O)C6=NC=CC=C6O

For research use only. We do not sell to patients.

Summary

Werner syndrome RecQ helicase-IN-4 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC 50 value of 0.06 µM. Werner syndrome RecQ helicase-IN-4 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-4 shows anticancer activity [1] .


IC50 & Target

IC 50 : 0.06 µM (WRN) [1]


In Vitro

Werner syndrome RecQ helicase-IN-4 (example 58) (0-10 µM; 8-20 days) shows antiproliferative activity with GI 50 s of 0.07, >10 µM for SW48, DLD1 WRN-KO cells, respectively [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay [1]

Cell Line: SW48, DLD1 WRN-KO cells
Concentration: 0-10 µM
Incubation Time: 8-20 days
Result: Showed antiproliferative activity with GI 50 s of 0.07, >10 µM for SW48, DLD1 WRN-KO cells, respectively.

In Vivo

Werner syndrome RecQ helicase-IN-4 (240 mg/kg; daily for 18 days) shows anticancer activity in mouse [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female Crl:NU(NCr)-Foxn1nu -Homozygous nude mice (SW48 xenografts cells) [1]
Dosage: 240 mg/kg
Administration: P.o.; daily for 18 days
Result: Inhibited tumor growth.

Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Please store the product under the recommended conditions in the Certificate of Analysis.